💬 Editorial: A sixth-generation high-sensitivity cardiac troponin T assay could allow clinicians to reassure more emergency department patients they are not having a myocardial infarction at presentation. ja.ma/4cpm1nr

In emergency department patients with suspected #AcuteCoronarySyndrome, a sixth-generation high-sensitivity cardiac troponin T assay identified twice as many low-risk patients for myocardial infarction at presentation compared with the current assay. ja.ma/494I7t8

At 20-year follow-up after patent foramen ovale closure for paradoxical embolism, recurrent stroke was rare (<1%), while bleeding events occurred in 13% and were more frequent among women and those on long-term antithrombotic therapy. ja.ma/4cnoVsY

Genotype-positive #FamilialHypercholesterolemia in US adults was linked to higher atherosclerotic cardiovascular disease rates and lower achievement of guideline-recommended LDL-C targets. ja.ma/4cgSNXO

In a US cohort, higher systolic #BloodPressure genetic risk was associated with new-onset #Hypertension after pregnancy, but elevated postpartum body mass index and hypertensive disorders of pregnancy were stronger risk factors. ja.ma/4bZPjJ7

Among patients with diabetes and multivessel coronary artery disease, ticagrelor was not noninferior to prasugrel for reducing death, myocardial infarction, stroke, or major bleeding at 1 year after percutaneous coronary intervention. ja.ma/4tSqepk

💬 Editorial: HeartSync-LBBP found #CSP superior to #BiVP for heart failure outcomes, whereas PhysioSync-HF found CSP inferior, emphasizing the importance of patient selection and operator proficiency. ja.ma/4csl9OH

Among asymptomatic patients with severe #AorticStenosis, higher midwall myocardial fibrosis burden was associated with increased death or unplanned hospitalization, but early valve intervention results did not differ by fibrosis burden. ja.ma/4mwEHVu

Patients with #HeartFailure showed increased myocardial fibroblast activation using [68Ga]FAPI-46 PET/MRI, with distinct patterns by cardiomyopathy etiology, highlighting activated fibroblasts as a potential therapeutic target. ja.ma/4thIybQ

📢 Now accepting applications: 2026–2027 JAMA Cardiology Editorial Fellowship Early-career cardiologists and researchers: elevate your academic trajectory by serving as a participating member of the JAMA Cardiology Editorial team. 🔗 Apply by May 15: ja.ma/4tOhKzH

In patients with #HeartFailure and #LBBB, conduction system pacing (#CSP) was inferior to biventricular pacing (#BiVP) for a composite of death, heart failure events, and LVEF change at 12 months. ja.ma/4my3U20

Higher aldosterone-renin ratios in older adults were linked to increased risk of atrial fibrillation and ischemic stroke, supporting the aldosterone pathway as a target for cardiovascular disease prevention. ja.ma/3Qm0oeZ

Food supplementation with medically tailored meals or fresh produce was feasible and well accepted in patients with #HeartFailure but did not reduce hospitalizations or emergency visits compared to usual care. ja.ma/4tCb3R8

💬 Editorial: Adverse pregnancy outcomes, especially hypertensive disorders, are linked to higher risk of premature #CardiovascularDisease. Pregnancy presents a key window for CV risk assessment and counseling. ja.ma/3NLB5Cr

In a population-based cohort, third-trimester levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and high-sensitivity cardiac troponin I were independently associated with greater long-term #CardiovascularDisease risk in pregnant women. ja.ma/3O1U2Rr

Congratulations to Barbara Casadei, Head of NHLI, on her appointment as Editor in Chief of @jamacardiology.com 👏 JAMA Cardiology publishes world-leading research in cardiovascular medicine and surgery, with over six million annual article views and downloads.

Among patients with anterior myocardial infarction, adding low-dose rivaroxaban to dual antiplatelet therapy did not significantly reduce left ventricular thrombus formation at 1 month but increased minor bleeding. ja.ma/4e6hdo5

Burst exercise testing detected more severe ventricular arrhythmias and prompted treatment escalation more often than the Bruce protocol in patients with #CPVT, with no observed safety concerns. ja.ma/3O2X0Fi

In a US cohort, higher systolic #BloodPressure genetic risk was associated with new-onset #Hypertension after pregnancy, but elevated postpartum body mass index and hypertensive disorders of pregnancy were stronger risk factors. ja.ma/4vllJW3

RBM20 truncating variants were associated with reduced lifetime penetrance and milder disease in #DilatedCardiomyopathy compared to pathogenic RBM20 or titin variants, suggesting a low-effect role in arrhythmogenic cardiomyopathy. ja.ma/4ttY8ki

Food supplementation with medically tailored meals or fresh produce was feasible and well accepted in patients with #HeartFailure but did not reduce hospitalizations or emergency visits compared to usual care. ja.ma/4shaJ9i

#Type2Diabetes patients at high cardiovascular risk receiving oral #semaglutide demonstrated early and sustained improvements in glycated hemoglobin, body weight, systolic blood pressure, and lipid profiles vs placebo. ja.ma/47JFQTG

In a US cohort, higher systolic #BloodPressure genetic risk was associated with new-onset #Hypertension after pregnancy, but elevated postpartum body mass index and hypertensive disorders of pregnancy were stronger risk factors. ja.ma/4s7jJxK

💬 Editorial: Among patients with #HFrEF in the Veterans Health Administration, fewer than 1 in 6 achieved quadruple therapy and the median time to initiation exceeded 6 months. ja.ma/41Ef3Vj

Among US veterans with #HeartFailure with reduced ejection fraction, fewer than one-quarter achieved quadruple guideline-directed medical therapy within 2.9 years, and medication copays were associated with lower rates of therapy achievement. ja.ma/4tqmTxP

Early and continuous acoramidis treatment in #ATTRCM yields sustained reductions in mortality and cardiovascular hospitalization, stabilizes biomarkers and health status, and exhibits durable safety through 54 months. #ACC26 @accintouch.bsky.social ja.ma/4bGqr9d

📚🫀 Read all the JAMA Cardiology papers presented today at #ACC26, including Pregnancy-Associated Spontaneous Coronary Artery Dissection. ja.ma/4dgCVpg

Among women with #PSCAD, compared to #NPSCAD, rates of assisted reproductive technology use, #preeclampsia, #multigravidity, and severe acute #coronary events were higher; LVEF recovery was less likely at 1 year. #ACC2026 @accintouch.bsky.social ja.ma/4vdcTd0

Extended low-dose #Apixaban reduced symptomatic #SuperficialVeinThrombosis risk among patients with provoked venous thromboembolism and enduring recurrence risk factors. #ACC2026 @accintouch.bsky.social ja.ma/4dch7Li

Among patients with #AtrialFibrillation, higher serum neurofilament light chain levels were associated with increased risk of major vascular events, stroke, cardiovascular death, and heart failure hospitalization. #ACC2026 @accintouch.bsky.social ja.ma/3O4Tkmk

At #ACC26? 📚 Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation (DECAF RCT) From JAMA 🔓 Free to read online ja.ma/4sIaUM6

📊 JAMA Clinical Guidelines Synopsis: The 2025 ACC/AHA guideline recommends home and office #BloodPressure monitoring to confirm diagnosis and titrate medications, with a target blood pressure of <130/80 mm Hg for most adults. ja.ma/488PCPd

💬 Editorial: In the VESALIUS-CV trial, evolocumab reduced major cardiovascular events in high-risk patients, including those with long-standing #diabetes, already receiving statins but not reaching LDL-C targets. #ACC26 @accintouch.bsky.social ja.ma/4s2r6Xs

From @jama.com: 📊 Research Summary: Among adults with high-risk #diabetes and elevated LDL cholesterol but no significant atherosclerosis, adding evolocumab to statin therapy reduced first major cardiovascular events. #ACC26 @accintouch.bsky.social ja.ma/4lVsppF

From @jama.com: Among adults with high-risk #diabetes and elevated LDL cholesterol, evolocumab combined with statins reduced rates of major cardiovascular events compared to statin alone. #ACC26 @accintouch.bsky.social ja.ma/4lZZT6f

📍 At #ACC26? Attend the JAMA_current Late-Breaking Clinical Trials session: 📅 Mar 28 | 3:35 to 4:45 PM 📍 Main Tent, Great Hall Chaired by JAMA Executive Editor Greg Curfman, MD

💬 Editor's Note: In HFmrEF/HFpEF, modest clinical and biomarker declines precede sudden death, but similar patterns occur before other fatal outcomes, limiting risk prediction specificity. #ACC26 @accintouch.bsky.social ja.ma/41jAOK9

Biomarker-driven #HFpEF risk stratification using the EMPEROR-Preserved model identified higher absolute benefit from finerenone for patients at greatest baseline risk, while relative treatment effect remained uniform. #ACC26 @accintouch.bsky.social ja.ma/4tjaGuN

In #HFmrEF/#HFpEF, sudden death was usually preceded by modest worsening of symptoms, declining quality of life, and rising NT-proBNP, similar to other causes of death, limiting prediction specificity. #ACC26 @accintouch.bsky.social ja.ma/41tWm6G

💬 Editor's Note: Dual incretin therapy may improve cardiorenal outcomes when broader endpoints are considered, but robust superiority trials are needed for #Type2Diabetes. #ACC26 @accintouch.bsky.social ja.ma/3O6evo0

In patients w/ type 2 #diabetes and #cardiovascular disease, the dual #GLP1/glucose-dependent insulinotropic polypeptide agonist #tirzepatide was associated w/ a lower incidence of major cardiorenal events compared with dulaglutide. #ACC26 @accintouch.bsky.social ja.ma/4s1pCfZ

📍 At #ACC26? Join the Joint @accintouch.bsky.social / JAMA Late‑Breaking Clinical Trials II session: 📅 Today, March 28 ⏰ 3:45–4:45 PM CT 📍 Main Tent, Great Hall Chaired by JAMA Executive Editor Greg Curfman, MD.

📍 #ACC26 attendees, don’t miss the JAMA Late‑Breaking Clinical Trials II session: 📅 Mar 28 | 3:45–4:45 PM CT 📍 Main Tent, Great Hall Chaired by JAMA Executive Editor Greg Curfman, MD.

Major bleeding after left atrial appendage occlusion was most frequent in the first 6 months, and associated with older age, diabetes, prior bleeding, kidney disease, and increased risk of stroke and mortality. ja.ma/3Q5MsWj

#Type2Diabetes patients at high cardiovascular risk receiving oral #semaglutide demonstrated early and sustained improvements in glycated hemoglobin, body weight, systolic blood pressure, and lipid profiles vs placebo. ja.ma/4lVmHUB

📍 At #ACC26? Join the JAMA Late‑Breaking Clinical Trials II session: 📅 Sat, Mar 28 | 3:45–4:45 PM CT 📍 Main Tent, Great Hall Chaired by JAMA Executive Editor Greg Curfman, MD

Attending #ACC26? Visit our attendee page to: 📚 Read recent articles & podcasts 🤝 Meet editors ✍️ Find author resources ja.ma/4bBsSK8

Heading to #ACC26? 🤝 Meet Robert Harrington, MD, Associate Editor, JAMA Cardiology 📍 Booth 1906 ⏰ Sun, Mar 29 | 10:00 -10:30 AM

Major bleeding after left atrial appendage occlusion was most frequent in the first 6 months, and associated with older age, #diabetes, prior bleeding, kidney disease, and increased risk of stroke and mortality. ja.ma/4dCJVwE

💬 Editor's Note: Oral #GLP1RA therapies offer new options for cardiovascular risk reduction, supporting shared decision-making for patients and clinicians as the landscape evolves beyond injectable agents. ja.ma/4dHrVRK